Maxim starts Abacus Global at Buy with revenue seen more than doubling

As previously reported, Maxim initiated coverage of Abacus Global (ABL) with a Buy rating and $14 price target Abacus is the second-largest and only publicly traded company focused on life settlements, an uncorrelated alternative asset class to the stock market, and with two asset management acquisitions in Q4, Abacus is positioned to more than double revenue and adjusted EBITDA in 2026, the analyst tells investors.